Sort
10,766 grants matching “checkpoint inhibitor”
Identifying the Role of Tumor Cell Intrinsic DNMT1 in Anti-Tumor Immunity in Pancreatic Ductal Adenocarcinoma
$51,752Erin Elizabeth Hollander · University Of Pennsylvania · F30 · FY2022 · CA
Impact of local and systemic cellular senescence toward Triple Negative Breast Cancer growth and drug therapy
$51,752Irfan Khan · Georgetown University · F30 · FY2022 · CA
Mechanistic Dissection and Therapeutic Targeting of B7x in Cancer
$51,752Christopher D Nishimura · Albert Einstein College Of Medicine · F30 · FY2022 · CA
Elucidating the protective role of stromal fibrosis to radiation-induced tumor immunity
$51,752Varintra Edlyn Lander · Washington University · F30 · FY2022 · CA
The Wnt-IRF8 axis: a Novel Regulator of Myeloid-Derived Suppressor Cell Biology
$51,752Elliot David Kramer · Roswell Park Cancer Institute Corp · F30 · FY2022 · CA
Activation of Inflammatory Responses Upon Replication Stress in Basal-Like Breast Cancer
$51,752Elizabeth Frances Gorodetsky · New York University School Of Medicine · F30 · FY2022 · CA
Contribution of PAG to Immune Synapse Organization and PD-1 Function
$51,752Emily Kathryn Moore · Columbia University Health Sciences · F30 · FY2022 · CA
Rab4A Control of Liver Dysfunction in Mouse Models of Systemic Lupus Erythematosus.
$51,752Akshay Patel · Upstate Medical University · F30 · FY2022 · DK
Identifying and Targeting Master Regulators of Drug Resistance in Lung Adenocarcinoma through Network Analysis of Tumor Transcriptomic Data
$51,752Aaron Timothy Griffin · Columbia University Health Sciences · F30 · FY2022 · CA
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition
$51,752Daniel R Principe · University Of Illinois At Chicago · F30 · FY2022 · CA
Development of a tumor-activated IL12 prodrug to treat solid tumors
$51,752Benjamin Moon · Ut Southwestern Medical Center · F30 · FY2022 · CA
Glycolysis and Glutaminase in CD8 T cell differentiation and anti-tumor immunity
$51,752Matthew Zachary Madden · Vanderbilt University · F30 · FY2022 · CA
Clinical trial data analysis to design novel treatment regimens in oncology
$51,752Deborah Plana · Harvard Medical School · F30 · FY2022 · CA
Discovering Network-Based Drivers of Single-Cell Transcriptional State in Tumor Immune Microenvironment to Reveal Immuno-Therapeutic Targets and Treatment Synergies
$51,752Aleksandar Zoran Obradovic · Columbia University Health Sciences · F30 · FY2022 · CA
Elucidating mechanisms of mucin-mediated immune regulation in cancer
$51,657Jessica C Stark · Stanford University · F32 · FY2020 · CA
PBRM1 bromodomain missense mutations in ccRCC vascular signaling
$51,628Karina Lynn Bursch · Medical College Of Wisconsin · F30 · FY2025 · CA
The role of CCR6 in Pancreatic Cancer and Tregs
$51,628Donovan G Drouillard · Medical College Of Wisconsin · F30 · FY2025 · CA
Cyclin-Dependent Kinase Inhibition During S Phase
$51,552Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2013 · CA
The use of epigenetic therapy to activate an immune response in ovarian cancer
$51,530Katherine B Chiappinelli · Johns Hopkins University · F32 · FY2014 · CA
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$51,338Heide L Ford · University Of Colorado Denver · R01 · FY2018 · CA
Regulating the ATR checkpoint through protein ubiquitylation
$51,326Richard C. Centore · Massachusetts General Hospital · F32 · FY2011 · GM
Project 1: Developing immune checkpoint controlled-release biomaterials for cancer immunotherapy
$51,262Todd D Giorgio · Vanderbilt University Medical Center · U54 · FY2021 · CA
PBRM1 bromodomain missense mutations in ccRCC vascular signaling
$51,064Karina Lynn Bursch · Medical College Of Wisconsin · F30 · FY2024 · CA
The role of CCR6 in Pancreatic Cancer and Tregs
$51,064Donovan G Drouillard · Medical College Of Wisconsin · F30 · FY2024 · CA
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition
$51,036Daniel R Principe · University Of Illinois At Chicago · F30 · FY2021 · CA